Approvals/TGA/CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials

Approved

STANDARD

CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials

ViiV Healthcare Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: cd5547505b35cd0f
Product Name: CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials
Artg Id: 323784
Artg Name: CABENUVA cabotegravir 400 mg/2 mL plus rilpivirine 600 mg/2 mL prolonged-release suspensions for injection vials
Sponsor: ViiV Healthcare Pty Ltd
Company Detail Path: /organization/viiv-healthcare-pty-ltd
Artg Date: 2021-02-23
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/daf6903dda2657a6b055c446e9f2d683.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/1f89b9712273adf7da30e6423fdb0297.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

cd5547505b35cd0f

Type

Standard